Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Targeting DNA2 Overcomes Myeloma Cells' Metabolic Reprogramming in Response to DNA Damage

Natthakan Thongon, Andrea Santoni, Jintan Liu, Natalia Baran, Feiyang Ma, Christopher Jackson, Pamela Lockyer, Irene Ganan-Gomez, Vera Adema, Ashley Rose, Matteo Marchesini, Yun Qing, Min Jin Ha, Caleb Class, Matteo Pellegrini, Lin Tan, Philip Lorenzi, Marina Konopleva, Simona Colla

Blood (2021) 138 (Supplement 1): 1573.

https://doi.org/10.1182/blood-2021-148992

Published: 2021

Journal Articles

Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML

Faezeh Darbaniyan, Caleb Class, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Marcos Estecio, Yue Lu, Kelly A. Soltysiak, Kelly S. Chien, Hui Yang, Koji Sasaki, Irene Ganan-Gomez, Simona Colla, Kim-Anh Do, Guillermo Garcia-Manero, Yue Wei

Blood (2021) 138 (Supplement 1): 4652.

https://doi.org/10.1182/blood-2021-153698

Published: 2021

Journal Articles

Hypomethylating Agents Do Not Alter Novel Splicing Events in Myeloid Neoplasms

Hussein A Abbas, MDPhD, Feng Wang, PhD, Yue Wei, PhD, Hui Yang, MD PhD, Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Caleb Class, PhD, Faezeh Darbaniyan, PhD, Jianhua Zhang, PhD, Andy Futreal, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-140142

Published: 2020

Journal Articles

Highly-Sensitive DNA Hydroxymethylation Analysis in Myelodysplastic Syndromes (MDS)

Jia Li, PhD, Yue Wei, PhD, Minjung Lee, Hui Yang, MD PhD, Caleb Class, PhD, Stefan Siwko, Yubin Zhou, PhD, Deqiang Sun, PhD, Guillermo Garcia-Manero, MD, Yun Huang, PhD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-137733

Published: 2020

Journal Articles

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141411

Published: 2020

Journal Articles

KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice

Yue Wei, PhD, Hong Zheng, Naran Bao, Rashmi Kanagal-Shamanna, MD, Caleb Class, PhD, Hui Yang, PhDMD, Guillermo Montalban Bravo, MD, Irene Ganan-Gomez, PhD, Kelly Soltysiak, PhD, Kim-Ann Do, Simona Colla, PhD, Carlos E. Bueso-Ramos, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 562.

https://doi.org/10.1182/blood-2019-122574

Published: 2019

Journal Articles

Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes

Blood (2019) 134 (Supplement_1): 1711.

https://doi.org/10.1182/blood-2019-124978

Published: 2019

Journal Articles

Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes

Blood (2019) 134 (Supplement_1): 1715.

https://doi.org/10.1182/blood-2019-129141

Published: 2019

Journal Articles

Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban-Bravo, MD, Caleb Class, PhD, Koji Sasaki, MD, Christopher B. Benton, MD, Kelly Soltysiak, PhD, Elias Jabbour, MD, Tapan M. Kadia, MD, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Mark Routbort, MD PhD, Irene Ganan-Gomez, PhD, Yue Wei, PhD, Gautam M. Borthakur, MD, Farhad Ravandi, MD, Kim-Anh Do, PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 1719.

https://doi.org/10.1182/blood-2019-130545

Published: 2019

Journal Articles

Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome

Ali Sakhdari, MD MSc, Caleb Class, PhD, Guillermo Montalban-Bravo, MD, Koji Sasaki, MD, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Joseph D. Khoury, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, L. Jeffrey Medeiros, MD, Rashmi Kanagal-Shamanna, MD

Blood (2019) 134 (Supplement_1): 3016.

https://doi.org/10.1182/blood-2019-131774

Published: 2019

Journal Articles

Comprehensive DNA 5-Hydroxymethylation Landscapes in Myelodysplastic Syndromes (MDS)

Jia Li, PhD, Yue Wei, PhD, Minjung Lee, MS, Caleb Class, PhD, Hui Yang, PhDMD, Deqiang Sun, PhD, Guillermo Garcia-Manero, MD, Yun Huang, PhD

Blood (2019) 134 (Supplement_1): 2996.

https://doi.org/10.1182/blood-2019-128599

Published: 2019

Journal Articles

Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes

Guillermo Montalban-Bravo, MD, Caleb Class, PhD, Irene Ganan-Gomez, PhD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Guillaume Richard-Carpentier, MD, Kiran Naqvi, MDMPH, Yue Wei, PhD, Hui Yang, PhDMD, Kelly Soltysiak, PhD, Kelly S. Chien, MD, Carlos E. Bueso-Ramos, MD PhD, Kim-Anh Do, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 3006.

https://doi.org/10.1182/blood-2019-124957

Published: 2019

Journal Articles

Overexpression of Histone Demethylase KDM6B in the Hematopoietic Compartment Promotes the Effect of Innate Immune Activation and Results in Myelodysplastic Syndrome (MDS)-like Phenotype in Mice

Yue Wei, PhD, Guillermo Garcia-Manero, MD, Hong Zheng, Yu Jia, Naran Bao, Shan Jiang, Joseph David Khoury, MD, Caleb Class, Simona Colla, PhD, Carlos E. Bueso-Ramos, MD PhD

Blood (2017) 130 (Supplement 1): 50.

https://doi.org/10.1182/blood.V130.Suppl_1.50.50

Published: 2017

NARROW

Targeting DNA2 Overcomes Myeloma Cells' Metabolic Reprogramming in Response to DNA Damage

Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML

Hypomethylating Agents Do Not Alter Novel Splicing Events in Myeloid Neoplasms

Highly-Sensitive DNA Hydroxymethylation Analysis in Myelodysplastic Syndromes (MDS)

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice

Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes

Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes

Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome

Comprehensive DNA 5-Hydroxymethylation Landscapes in Myelodysplastic Syndromes (MDS)

Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes

Overexpression of Histone Demethylase KDM6B in the Hematopoietic Compartment Promotes the Effect of Innate Immune Activation and Results in Myelodysplastic Syndrome (MDS)-like Phenotype in Mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only